Showing results (101-110 of 110) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The American Journal of Cardiology|February 5, 2004
Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantationChiara Pedone, Francesco Grigioni, Giuseppe Boriani, et al.BMC Genomics|February 22, 2011
TRAM (Transcriptome Mapper): database-driven creation and analysis of transcriptome maps from multiple sourcesLuca Lenzi, Federica Facchin, Francesco Piva, et al.ACS Chemical Neuroscience|May 23, 2023
PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer's DiseaseMelissa Guardigni, Letizia Pruccoli, Alan Santini, et al.Journal of Cellular Physiology|September 25, 2018
HDAC8 regulates canonical Wnt pathway to promote differentiation in skeletal musclesLuca Ferrari, Cinzia Bragato, Loredana Brioschi, et al.Experimental & Applied Acarology|January 5, 2023
Natural levels of Rhipicephalus microplus infestation and Anaplasma marginale infection in Angus and Ultrablack calvesAçucena Fragnan Frabetti, Luciana Morita Katiki, Laura Caetano, et al.Journal of Virology|July 13, 2018
Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Translocation in Nondividing CellsCindy Buffone, Alicia Martinez-Lopez, Thomas Fricke, et al.Cellular and Molecular Life Sciences : CMLS|November 25, 2025
Novel insights into the molecular mechanisms of LGMDD2: role of TNPO3 in experimental cell and zebrafish modelsM T Rodia, M Fazzina, Roberta Costa, et al.ACS Medicinal Chemistry Letters|April 19, 2019
Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's DiseaseAngela De Simone, Valeria La Pietra, Nibal Betari, et al.ACS Medicinal Chemistry Letters|September 19, 2019
Correction to "Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease"Angela De Simone, Valeria La Pietra, Nibal Betari, et al.Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.Pageof 11